Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAB-HCC trial of fecal microbiota transplant with atezolizumab + bevacizumab in immunotherapy-refractory hepatocellular carcinoma
2022-000234-42Phase 2Active
- Sponsor
- Medical University of Vienna
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Medical University of Vienna. Primary endpoint: Safety. Started Feb 2022; status: active.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2022-000234-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000234-42.